Document is current
Any future updates will be listed below
-
Authors
Carrera-Noguero, A. M.
Guilabert Mora, M.
Pérez-Jover, V.
Pola-Garcia, M.
Mira Solves, J. J.
Astier-Peña, M. P.
,
Cassetti, V.
Melús-Palazón, E.
Benedé-Azagra, B.
Gasch-Gallén, A.
Enríquez Martín, N.
Asencio Aznar, A.
Gimeno-Monterde, C.
Lou Alcaine, M. L.
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
Instituto de Salud Carlos III (PI20/00264)
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 9 July 2025
First Online: 23 August 2025
Declarations
:
: This study was conducted in accordance with the ethical principles of the Spanish Biomedical Research Law 14/2007 and approved by the Ethics Committee of Clinical Research of Aragón (CEICA) in its meeting on January 13, 2021 (Act No. 01/2021) C.I. PI20/606.Our study follows the Helsinki Declaration ().For all the phases involving participation of experts in the nominal group sessions and the Delphi survey, an informed consent form has been applied which explains the project, the participants’ implications and how the collected information will be used and managed.PHC teams, health asset providers and citizens who participate in the implementation of indicators in the second phase of the study have their informed consent.Most stakeholders that participate in the SPS process are represented in the research team and a local working group is actively collaborating with the study. The project is also receiving institutional support.
: Not applicable.
: The authors declare no competing interests.
